Skip to main content

#156471

Anti-phospho Pax3 [Ser201]

Cat. #156471

Anti-phospho Pax3 [Ser201]

Cat. #: 156471

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Phosphorylated Ser201 of Pax3

Class: Monoclonal

Application: WB

Reactivity: Human ; Mouse

Host: Rat

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Out of stock

Contributor

Inventor: Andrew Hollenbach

Institute: Louisiana University Health Sciences Center New Orleans (LSU)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-phospho Pax3 [Ser201]
  • Research fields: Developmental biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human ; Mouse
  • Host: Rat
  • Application: WB
  • Description: Pax3 is a transcription factor important for myogenesis and when dysregulated can cause pediatric solid muscle tumor alveolar rhabdomyosarcoma (ARMS). ARMS is primarily characterized by the t(2;13)(p35;p14) chromosomal translocation, which results in the oncogenic fusion protein Pax3-FOXO1. Using these phospho-specific antibodies it was demonstrated that the pattern of Pax3 phosphorylation at serines 201, 205, and 209 changes throughout early myogenic differentiation and that this pattern is different for Pax3-FOXO1 in primary myoblasts and in several ARMS cell lines.
  • Immunogen: synthetic peptide: NH2-CSERASAPQ(pS)DEG-CO2
  • Recommended controls: IgG

Target Details

  • Target: Phosphorylated Ser201 of Pax3
  • Tissue cell line specificity: IgG
  • Target background: Pax3 is a transcription factor important for myogenesis and when dysregulated can cause pediatric solid muscle tumor alveolar rhabdomyosarcoma (ARMS). ARMS is primarily characterized by the t(2;13)(p35;p14) chromosomal translocation, which results in the oncogenic fusion protein Pax3-FOXO1. Using these phospho-specific antibodies it was demonstrated that the pattern of Pax3 phosphorylation at serines 201, 205, and 209 changes throughout early myogenic differentiation and that this pattern is different for Pax3-FOXO1 in primary myoblasts and in several ARMS cell lines.

Applications

  • Application: WB

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Loupe et al. 2015. Oncogenesis. 4:e145. PMID: 25821947.
  • Dietz et al. 2011. Int J Biochem Cell Biol. 43(6):936-45. PMID: 21440083.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.